We believe that Boston Scientific can raise its offer to $78 a share and still maintain an investment-grade credit rating.

Although the strategic rationale for combining Boston Scientific and Guidant appears compelling, we have lingering concerns.

We suspect the new Boston Scientific offer was developed with input from the Guidant board, so it's likely that the Guidant board will declare it superior to J&J's latest offer.

This investment bid is being made as part of the Boston Globe's long-term strategic plan to solidify its position as the leading news and advertising media in New England.

This investment bid is being made as part of the Boston Globe's long-term strategic plan to solidify its position as the leading news and advertising media in New England,

South Boston is very dynamic. When we bought this property, we were banking on all this planned investment in the area.